Evidence map›Paper›PMID 37946204›Full record

ArticleBMC biology2023

Transcription dosage compensation does not occur in Down syndrome.

Samuel Hunter, Jo Hendrix, Justin Freeman, Robin D Dowell, Mary A Allen

Abstract read
In one paragraph

Article in BMC biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Consequences of gaining an extra chromosome.Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology · 2023
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Samuel HunterMolecular, Cellular, and Developmental Biology, University of Colorado Boulder, Boulder, 80301, USA.
Jo HendrixBioFrontiers Institute, University of Colorado, Boulder, 80309, USA.
Justin FreemanBioFrontiers Institute, University of Colorado, Boulder, 80309, USA.
Robin D DowellMolecular, Cellular, and Developmental Biology, University of Colorado Boulder, Boulder, 80301, USA.
Mary A AllenBioFrontiers Institute, University of Colorado, Boulder, 80309, USA. Mary.A.Allen@colorado.edu.ORCID 0000-0001-7490-0165

Funding

Mediator kinases as interferon antagonists in Down SyndromeR01AI156739 · NIAID · UNIVERSITY OF COLORADO · PI TAATJES, DYLAN J · 2020 to 2024
$2.4M
Function of RUNX1 in diverse Down syndrome tissuesR01HL156475 · NHLBI · UNIVERSITY OF COLORADO · PI ALLEN, MARY A · 2021 to 2023
$2.1M
Measuring global, loci-specific RNA degradation to interrogate RNA dysregulation in down syndrome during developmentR03HD103995 · NICHD · UNIVERSITY OF COLORADO · PI DOWELL-DEEN, ROBIN DEANNE · 2020 to 2020
$301k
NHLBI NIH HHS R01 HL156475NIAID NIH HHS R01 AI156739NICHD NIH HHS R03 HD103995ODCDC CDC HHS 1R03HD103995
6 · The paper itself

Abstract

backgroundThe increase in DNA copy number in Down syndrome (DS; caused by trisomy 21) has led to the DNA dosage hypothesis, which posits that the level of gene expression is proportional to the gene's DNA copy number. Yet many reports have suggested that a proportion of chromosome 21 genes are dosage compensated back towards typical expression levels (1.0×). In contrast, other reports suggest that dosage compensation is not a common mechanism of gene regulation in trisomy 21, providing support to the DNA dosage hypothesis.

resultsIn our work, we use both simulated and real data to dissect the elements of differential expression analysis that can lead to the appearance of dosage compensation, even when compensation is demonstrably absent. Using lymphoblastoid cell lines derived from a family with an individual with Down syndrome, we demonstrate that dosage compensation is nearly absent at both nascent transcription (GRO-seq) and steady-state RNA (RNA-seq) levels. Furthermore, we link the limited apparent dosage compensation to expected allelic variation in transcription levels.

conclusionsTranscription dosage compensation does not occur in Down syndrome. Simulated data containing no dosage compensation can appear to have dosage compensation when analyzed via standard methods. Moreover, some chromosome 21 genes that appear to be dosage compensated are consistent with allele specific expression.

Indexed as

Down SyndromeDNADosage Compensation, GeneticGene Expression RegulationHumansX ChromosomeDNADNA-seqDosage compensationDown syndromeGRO-seqRNA-seq

Identifiers

PMID37946204
PMCPMC10636926

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.